0001104659-20-141088.txt : 20210104 0001104659-20-141088.hdr.sgml : 20210104 20201231195106 ACCESSION NUMBER: 0001104659-20-141088 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210104 DATE AS OF CHANGE: 20201231 EFFECTIVENESS DATE: 20210104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-385028 FILM NUMBER: 201429750 BUSINESS ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 781-788-9043 MAIL ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 D 1 primary_doc.xml X0708 D LIVE 0001372514 EYEGATE PHARMACEUTICALS INC 271 WAVERLEY OAKS ROAD SUITE 108 WALTHAM MA MASSACHUSETTS 02452 781-788-9043 DELAWARE None None Corporation true Stephen From 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Director President and Chief Executive Officer Sarah Romano 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Chief Financial Officer Bernard Malfroy-Camine 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Paul Chaney 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Steven Boyd 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Morton Goldberg 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Praveen Tyle 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Thomas Hancock 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Keith Maher 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Pharmaceuticals Decline to Disclose 06b false 2020-12-18 false true true This Form D relates to the issuance of shares of common stock and Series D Convertible Preferred Stock as merger consideration to the former stockholders of Panotpes Pharma G.m.b.H and its financial advisor. 0 Indefinite 3203083 Indefinite 884,222 shares of common stock and 45.8923 shares of Series D Convertible Preferred Stock were issued on 12/18/2020. Additional shares may include up to $1.5 million in value of holdback shares and up to $9.5 million in value of potential earnout shares. false 15 0 0 0 false EYEGATE PHARMACEUTICALS INC /s/ Sarah Romano Sarah Romano Chief Financial Officer 2020-12-31